Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - antioxydants - primary prevention

cardiovascular prevention - antioxydants - all type of patients

Related trials

PHS II vitamin C, 2008 - vitamin C vs placebo

POPADAD (antioxydant), 2008 - combination vs placebo

ARISE, 2008 - succinobucol vs placebo

PHS II vitamin E, 2008 - vitamin E vs placebo

WACS beta-caroten, 2007 - beta carotene vs placebo

WACS vitamin E, 2007 - vitamin E vs placebo

WACS vitamin C, 2007 - vitamin C vs placebo

WHS vitamin E, 2005 - vitamin E vs placebo

SUVIMAX, 2005 - combination vs placebo

PHS II beta carotene, 2003 - combination vs placebo

Tepel, 2003 - acetylcysteine vs placebo

WAVE (Waters), 2002 - combination vs placebo

HPS antioxidant, 2002 - combination vs placebo

HATS, 2001 - combination vs placebo

PPP, 2001 - vitamin E vs control

AREDS, 2001 - vitamin E vs placebo

HOPE, 2000 - vitamin E vs placebo

ASAP, 2000 - vitamin E vs placebo

WHS beta carotene, 1999 - beta carotene vs placebo

GISSI, 1999 - vitamin E vs control

NSCP (Green) beta carotene, 1999 - beta carotene vs placebo

MVP, 1997 - combination vs placebo

PHS beta carotene, 1996 - beta carotene vs placebo

CARET beta carotene, 1996 - beta carotene vs placebo

CHAOS, 1996 - vitamin E vs placebo

See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of antioxydants
  • All clinical trials of combination

    PHS II beta carotene study, 2003

    [NCT00270647] download pdf: combination | antioxydants for cardiovascular prevention


    Studied treatment 400 IU of vitamin E every other day and 500 mg of vitamin C daily
    Control treatment placebo
    Remarks factorial design with : beta-caroten, vit E and ascorbic acid, multivitamin


    Patients US male physicians enrolled, aged 50 years or older
    Remarks 7641 men from the PHS agreed to participate in the PHSII and, beginning in August 1997, were randomized to PHSII study treatments. Treatment assignment to beta carotene or placebo was retained from the PHS (although participants may have stopped taking beta carotene during the 18-month interval between studies), and the men were newly randomized to receive vitamin E, ascorbic acid, multivitamin, or placebo.

    Method and design

    Randomized effectives 2967 / 2989 (studied vs. control)
    Design Factorial plan
    Blinding double-blind
    Follow-up duration 8 years
    Primary endpoint cardiovascular events

    Remarks / Comments

    only a substudy of cognitive function was published


    No results available for this trial - no clinical endpoint reported

    Meta-analysis of all similar trials:

    antioxydants in cardiovascular prevention for primary prevention

    antioxydants in cardiovascular prevention for all type of patients


    Trials register # NCT00270647
    • Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials.. Ann Epidemiol 2000;10:125-34
      Pubmed | Hubmed | Fulltext
    • Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II.. Arch Intern Med 2007;167:2184-90
      Pubmed | Hubmed | Fulltext
    • Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.. JAMA 2008;300:2123-33
      Pubmed | Hubmed | Fulltext

    (c) 2004-2012 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend